NN&I - June 2010
4 Nephrology News & Issues June 2010Subscribe to our free eNewsletter at www.nephronline.comContents Vol. 24, No. 7, June 2010 First Word 8Will health care reform put CKD care in the spotlight? Mark E. NeumannNational 10GAO reviews potential impact of ESRD bundle \037 Dialysis groups, senators raise concerns over proposed \037 VA payment cuts for ESRD CMS clarifies vascular access infection modifiers \037 Letters \037 2010 Renal Resource & Buyer's Guide update \037Health Care Beat 14Democrats begin battle with insurance companies Thomas KeatingBusiness 17FDA forces Baxter to recall all Colleague Volumetric \037 Infusion Pumps DaVita to buy clinics from University of Chicago \037 American Renal sold for about $450m, report says \037 Forecast: Global drug sales to top $1 trillion by 2014 \037 Eli Lilly says health care reform caused Q1 \037 revenue to drop Taking Stock \037 Genzyme buys back $2B in stock after investors' anger \037 Amylin loss narrows on lower expenses, despite \037 Byetta's sag Merck halts development on its rival drug to \037 Amgen's Aranesp Stocks in the News \037 - Q1 reports from Fresenius, NxStage, and RockwellClinical 21Anemia tougher to tackle in black children with \037 kidney disease Takeda submits new drug application for hypertension \037 treatment azilsartan medoxomil Protein loss in the urine harmful for people with high \037 blood pressure High vitamin B doses may accelerate kidney damage \037 Nephrotic Syndrome focus of NEPTUNE Project \037Diabetes Watch 24After 710 deaths and 87 product recalls, FDA tightens \037 scrutiny of drug pumps Victoza trumps Januvia in reducing blood sugar \037 Phase 3 trial for lixisenatide successful \037 MannKind's inhaled insulin device Afrezza moves forward \037 Genetic mutations may cause type 1 \037 High-heated food may cause type 2 \037 Cover Story 30As part of the new Conditions for Coverage, dialysis clinics must perform monitoring and surveillance of the vascular access. But is surveillance justi\037 ied? The writers of our cover story this month disagree on whether it may prove to be a cost-effective tool in access management or whether the evidence does not support the perceived value. Which direction is right for vascular access surveillance? A debate. Contents_NNI0610_3.indd 4 5/14/10 5:42:41 PM
You must have JavaScript enabled to view digital editions.
